Bevacizumab, a humanized monoclonal antibody produced from Chinese hamster ovary (CHO) cells [119] targeting VEGF, is a major downstream target of HIF-1α and can reduce angiogenesis and tumor growth [120]. Here, HIF1A is linked to neoplasm.